Moleculin Biotech (MBRX) shares dropped about 19% in recent Wednesday trading after the company said no patients achieved complete response in the phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma lung metastases, a type of cancer.
The trial, however, demonstrated a clinical benefit rate of 59.4%, primarily comprising 18 cases of stable disease and one partial response, the company said.
The median progression-free survival in the 36 subjects participating in the trial was 63 days, while median overall survival clocked in at 411 days, the company said.
In the phase 2 portion of the study, which was made up of 17 subjects, the median progression-free survival was 105 days, with overall survival coming in at 13.5 months, the company added.
Annamycin holds the US Food and Drug Administration's orphan drug designation for the treatment of soft tissue sarcoma.
Price: 0.68, Change: -0.16, Percent Change: -18.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.